Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy

Documenti analoghi

• Mithramycin SK, A Novel Antitumor Drug with Improved Therapeutic Index, Mithramycin SA, and Demycarosyl-mithramycin SK: Three New Products Generated in the Mithramycin Producer Streptomyces argillaceus through Combinatorial Biosynthesis
  di: Remsing, Lily L., et al.
  Pubblicazione: (2003)
• Crystallization and X-ray diffraction properties of Baeyer–Villiger monooxygenase MtmOIV from the mithramycin biosynthetic pathway in Streptomyces argillaceus
  di: Wang, Chenchen, et al.
  Pubblicazione: (2005)
• Identification of Two Genes from Streptomyces argillaceus Encoding Glycosyltransferases Involved in Transfer of a Disaccharide during Biosynthesis of the Antitumor Drug Mithramycin
  di: Fernández, Ernestina, et al.
  Pubblicazione: (1998)
• Cellular and Molecular Consequences of Peroxisome Proliferator-Activated Receptor-γ Activation in Ovarian Cancer Cells
  di: Vignati, Sara, et al.
  Pubblicazione: (2006)
• Cloning and insertional inactivation of Streptomyces argillaceus genes involved in the earliest steps of biosynthesis of the sugar moieties of the antitumor polyketide mithramycin.
  di: Lombó, F, et al.
  Pubblicazione: (1997)